secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zura Bio Ltd (ZURA)
CIK:        0001855644
Form:       8-K
Filed at:   2025-10-10T23:59:59+00:00
Accession:  0001104659-25-098546
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

CEO Robert Lisicki takes medical leave; COO Kim Davis appointed interim CEO effective Oct 10
--------------------------------------------------------------------------------

- CEO Robert Lisicki informed Zura Bio of a medical leave of absence starting October 10, 2025.
- Board appointed Kim Davis (COO, CLO, Corporate Secretary) as interim CEO effective October 10, 2025.
- Davis will serve as interim CEO in addition to her current duties as COO, CLO, and Corporate Secretary.
- No arrangement, transactions under Item 404(a), or family relationships disclosed related to appointment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1855644/000110465925098546/0001104659-25-098546-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1855644/000110465925098546/tm2528470d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-098546

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer